Important step for European security of supply with medical isotopes
Jan van den Heuvel, deputy Director-General for medical radioisotopes at the Netherlands Ministry of Health, welcomes the approval of the the Molybdenum-99-producing irradiation facility at FRM II: „Ensuring security of supply of medical radioisotopes in the European Union (EU) is of upmost importance for European patients to tackle diseases such as cancer. We congratulate Germany and FRM II with this step, bringing Europe a step closer to ensuring the security of supply within its ageing production infrastructure. Without initiatives like these, European patients will not be ensured access to vital treatments.”
Manufacture of an important means of cancer diagnosis at the research neutron source
With a weekly production target of 16,000 Curie (Ci) of Mo-99-Activity - this figure refers to the activity immediately following irradiation - the FRM II kann meet a large proportion of Europe’s demand for cancer diagnosis isotopes. The completion and installation of the facility are planned for the coming years.